CSS LLC’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-10,613
Closed -$819K 737
2022
Q4
$819K Sell
10,613
-787
-7% -$47K 0.05% 297
2022
Q3
$509K Buy
+11,400
New +$570K 0.02% 516
2022
Q1
Sell
-18,549
Closed -$575K 1166
2021
Q4
$701K Buy
18,549
+12,111
+188% +$446K 0.02% 538
2021
Q3
$212K Buy
6,438
+338
+6% +$13.2K 0.01% 863
2021
Q2
$412K Sell
6,100
-1,000
-14% -$60K 0.02% 681
2021
Q1
$402K Buy
7,100
+4,700
+196% +$331K 0.02% 629
2020
Q4
$196K Buy
2,400
+500
+26% +$37.4K 0.01% 636
2020
Q3
$135K Sell
1,900
-1,591
-46% -$124K 0.01% 622
2020
Q2
$287K Buy
+3,491
New +$269K 0.02% 447
2020
Q1
Sell
-69,548
Closed -$5.67M 621
2019
Q4
$7.19M Buy
+69,548
New +$2.81M 0.4% 52

Other funds holding AXSM

CSS LLC's AXSM Position: Q1 2023 in Review

CSS LLC sold out of Axsome Therapeutics (AXSM) in Q1 2023, closing a stake of 10,613 shares — an estimated $819K sold.

CSS LLC first reported a position in AXSM in Q4 2019 and held it in 10 quarters. The position peaked at $7.19M in Q4 2019. 196 funds tracked by Wall St. Rank hold AXSM as of Q1 2023.

  • CSS LLC reported no remaining Axsome Therapeutics position as of Q1 2023 after selling out during the quarter.
  • CSS LLC sold 10,613 Axsome Therapeutics shares in Q1 2023, an estimated $819K.
  • CSS LLC first reported a position in Axsome Therapeutics in Q4 2019 and held it in 10 quarters.
  • CSS LLC's Axsome Therapeutics position peaked at $7.19M in Q4 2019.
  • 196 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2023.

Based on CSS LLC's 13F filing for Q1 2023, filed 15 May 2023.